CDK9 and pancreatic neoplasm: Importantly, no obvious off-target effects were observed in peripheral blood mononuclear and fibroblast cells.417 In 2021, Bian et al. reported a PROTAC B03, specifically targeting CDK9, which demonstrated 20-fold more potent degradation of CDK9 than the warhead alone in MV4-11 cells.425 Research has also shown that CDK9-targeting PROTAC selectively degraded CDK9 in pancreatic cancer cells and enhanced their sensitivity to venetoclax.426